Introduction
Gout is a disease featuring acute arthritis, joint deformity and severe pain caused
through the deposition of monosodium urate crystals in and around synovial tissue
[1]. Tophi are stone-like deposits of monosodium urate in the soft tissues, synovial
tissues, or bones adjacent to the joints.
The tophi can compromise joint motion and deteriorate bony structure, finally leading
to functional disability. Therefore, early treatment using uric acid lowering
agents is standard practice in gout patients to prevent the formation of tophi through
controlling uric acid levels.
